Chronic health conditions can be debilitating, and skin conditions in particular can make sufferers dread things like going to work, running errands or spending time outdoors. Millions suffer from ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Pharmaceutical Technology on MSN
J&J wins FDA approval for Icotyde to enter psoriasis pill market
J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results